Market Access

Stickiness in Tendering (Part 1): What it is and is it a Reality?

FIRST – WHAT IS STICKINESS? Co-written by Andra Mironescu, Senior Consultant, Pricing, Tenders & Contracts Throughout the course of this blog the reader will notice the frequent use of “Incumbent”…

Read Full Article

Trump’s Blueprint on International Drug Pricing; What to Expect

The U.S. always stood out as a different healthcare system. Well, maybe not anymore. The Trump Administration released an International Drug Pricing blueprint in 2018 and it was received with…

Read Full Article

Discount Safe Harbor Proposed Rule: How Process Works and What does it mean?

July 2019 Update As first reported by The Wall Street Journal and Axios on July 11, 2019, the Trump Administration has decided to abandon implementation of the proposed Discount Safe…

Read Full Article

Time for a Market Access Officer?

Market Access is becoming more and more challenging. This is irrespective of drug classes and new technologies. Payers are applying the same scrutiny on orphan drugs as on drugs for…

Read Full Article

How to Organize Your Market Access Functions

Market access functions in life sciences are always evolving. Disrupted by the increasing share of Biosimilars, companies are reorganizing themselves. In this environment, market access departments are absolutely required and…

Read Full Article

Biosimilars-The New Market Access Opportunity?

Biosimilars are on the agenda of several players in the pharmaceutical industry. Several companies’ new leg of growth seems to be the creation of a biosimilar franchise. The question is…

Read Full Article